A standard stool test grows bacteria in a lab to identify pathogens. It works for what it’s designed to do: detect Salmonella, Campylobacter, C. difficile. What it cannot do is describe the full microbial ecosystem. The human gut contains roughly 1,000 bacterial species at any time, the majority of which do not grow under standard lab conditions.¹ A culture-based test sees perhaps 2–3% of what is present.

Gut microbiome testing uses DNA sequencing directly from a stool sample (no growing required). Once DNA is extracted, the lab sequences either a conserved bacterial gene (16S rRNA) or all genetic material present (shotgun metagenomics). This gives a compositional picture: which species are present, in what relative abundance, and in some cases what metabolic functions those species are carrying out.

The relevant outputs for functional interpretation are: alpha diversity (richness and evenness of species in your sample), beta diversity (how your composition compares to a reference population), relative abundance of key commensals and potential pathogens, and short-chain fatty acid metabolites — particularly butyrate, propionate, and acetate, which reflect what your microbes are producing rather than who is there.²

16S rRNA sequencing targets a highly conserved region of bacterial DNA that acts as a biological barcode.¹ Every bacterium has this gene; the sequence varies just enough between species to distinguish them. The result is a compositional map of which bacterial groups are present and their relative abundance. Most consumer gut tests in Australia use 16S sequencing. It is cost-effective, well-validated for clinical research, and produces reports that are interpretable without specialist genomics training.

The limitation is resolution. 16S sequencing typically identifies bacteria to genus level reliably and to species level with variable accuracy depending on the gene region sequenced and the reference database used.³ It also cannot see fungi, viruses, or the metabolic pathways the bacteria are running: only who is present, not what they are doing.

Shotgun metagenomics sequences all DNA in the sample, including bacterial, fungal, viral, parasitic, and human. It can identify species with greater precision, map metabolic pathways and antibiotic resistance genes, and detect organisms that 16S misses.³ It also produces far more data, requiring sophisticated bioinformatic analysis to interpret. Clinically, shotgun metagenomics has been used to associate microbiome signatures with treatment resistance in conditions such as schizophrenia, where 16S data had previously given inconsistent results.¹⁰ At current prices, a good shotgun panel in Australia costs three to five times more than a 16S test.

PCR-based tests use targeted amplification to detect specific organisms or genes. They are precise, fast (same-day results are standard), and highly sensitive for known targets. A PCR test cannot discover organisms it was not designed to find; it answers a yes/no question for a pre-defined list. For clinical contexts where you are testing for a specific pathogen (H. pylori, Blastocystis, specific parasites), PCR is the right tool. For mapping the full ecosystem, it is not.

A clinically useful microbiome report does more than list bacteria. The minimum standard for a test worth paying for in Australia includes: a validated diversity score with comparison to a healthy reference population, relative abundance data at genus level or better, short-chain fatty acid quantification, and a flagging system for dysbiosis patterns rather than just individual species.

Reports that only return a species list without diversity metrics, SCFA data, or functional annotation are limited in clinical use. The presence of a species in isolation means little without context: how abundant it is relative to the broader community, and whether butyrate-producing species are sufficiently represented to maintain gut barrier function and produce the metabolites that reach the brain and the HPA axis.⁶

One variable that is rarely mentioned in consumer-facing materials but is substantively important is DNA extraction methodology. A 2021 study found that DNA extraction method explained nearly as much variance in microbiome composition results as true inter-individual biological differences.⁸ Similarly, sample collection conditions (stabilisation solution, temperature, storage duration) affect the profile returned.⁷ This is why two tests on the same person one week apart can return meaningfully different results if different methodologies are used. When evaluating a lab, ask whether their extraction methodology is published, validated, and consistent across samples.

Gut microbiome testing is clinically meaningful for people experiencing gut symptoms (bloating, altered motility, food reactivity), mood and cognitive disruption, immune system dysregulation, skin conditions with a gut component, and patterns of persistent fatigue that have not resolved through standard investigations.

The gut-brain axis is mechanistically established. The microbiome communicates with the central nervous system through vagal nerve signalling, immune activation, and metabolite production — including neurotransmitter precursors such as tryptophan (a serotonin precursor), GABA precursors produced by Lactobacillus species, and the short-chain fatty acids that cross the blood-brain barrier and influence neuronal activity.⁵ Research in 2021 identified the gut-brain axis as a meaningful contributor to executive function patterns, with microbial composition associated with cognitive and emotional processing capacity.⁵

The HPA axis (the body’s stress response system) is also bidirectionally linked to gut composition. Dysbiosis has been associated with HPA hyperactivation, and microbial metabolites including short-chain fatty acids modulate cortisol response.⁶ A preliminary study found that gut microbiome alpha diversity was positively associated with cortisol reactivity in infants, suggesting the microbiome shapes stress-response development from early life.¹¹

For high-performing individuals under chronic load (poor sleep, blunted recovery, cognitive fatigue), a gut microbiome panel alongside a functional stress hormone panel gives a more complete picture of what is driving the pattern. Gut testing alone rarely produces a complete explanation; the value is in how the result integrates with the broader clinical picture.